|
Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics
Wednesday, June 3, 2020
Innovative immuno-oncology biotech streamlines discovery of next-generation immunotherapies using Genedata enterprise solution
SAN FRANCISCO, May 26, 2020 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, including a portfolio of T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has implemented Genedata Biologics® within their R&D organization.
"Genedata Biologics is a perfect fit for our approach, because it comes with built-in functionalities that support the specialized immuno-oncology applications we require. For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology. "We are also looking forward to further automating our R&D processes and increasing throughput in our immunotherapy discovery programs."
Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies. Additionally, it will be used for advancing the R&D for multiple programs targeting cancer testis antigens and common mutations resulting in neoantigens. Genedata Biologics integrates all R&D workflows in a common workspace, giving the Gritstone teams comprehensive and real-time access to all relevant R&D data. Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.
Gritstone Oncology chose to operate Genedata Biologics as Software-as-a-Service (SaaS). This deployment option gives them an agile setup and increases operational efficiency, without the need to invest in the hardware and internal IT support required for an on-premise deployment.
"We are very pleased that Gritstone Oncology, an innovative leader in the field of personalized immunotherapies, has chosen Genedata to support their complex R&D processes," said Othmar Pfannes, Ph.D., CEO of Genedata. "The Genedata Biopharma Platform is a game changer in biopharma R&D. We help companies stay at the forefront of innovation with our continual investment in developing the platform to address new requirements, such as for TCRs, CAR Ts or novel cancer vaccines. Our goal is to digitalize and streamline all R&D workflows so that our partners can fully exploit the value of their data as they hunt for the next generation of therapies."
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
http://www.genedata.com
LinkedIn | Twitter | YouTube
Contact
Miles Fisher-Pollard
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
SOURCE Genedata
|
|
|
|
|
|
 |
Pedia.com Releases White Paper on Historic Offering, Underscores the Power of Credibility Marketing | Apr 26, 2024
|
|
RightOfTheDot Set to Host Groundbreaking Digital Asset Auction at NamesCon 2024 Featuring Super Premium Web2 and Web3 Digital Assets | Apr 26, 2024
|
|
Tier One Auto Suppliers Must Evolve with the Supply Chain to Access the 2030 US$15 Billion Next-Gen Cockpit Domain Controller Market | Apr 26, 2024
|
|
Global Kids' Eyewear Market to reach a valuation of US$ 77.0 billion by 2034, FMI Projection | Apr 26, 2024
|
|
AIShield Announces Groundbreaking AI Security Platform SecureAIx with Global Strategic Partners at GISEC 2024 | Apr 26, 2024
|
|
Cirrus by Panasonic® 2.0 Connected Vehicle Platform Advances Roadway Intelligence with Two-Way Communication and Insights That Traffic Operators Need | Apr 26, 2024
|
|
DFIN Completes Its First Tailored Shareholder Reports Test Filing Through ArcReporting | Apr 26, 2024
|
|
Applied Intuition and Audi partner on unified solution for AD release and lifecycle management | Apr 26, 2024
|
|
Listen Notes, Inc. Rolls Out Listen411: Redefining Podcast Transcription with A.I. Technology | Apr 26, 2024
|
|
Huawei and UNESCO Expand Opens Schools Project to New Countries | Apr 26, 2024
|
|
|
|
